FutureChem Co.Ltd (220100) - Total Liabilities

Latest as of March 2026: ₩16.93 Billion KRW ≈ $11.47 Million USD

Based on the latest financial reports, FutureChem Co.Ltd (220100) has total liabilities worth ₩16.93 Billion KRW (≈ $11.47 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore FutureChem Co.Ltd (220100) equity growth momentum to track the company's year-over-year net asset growth rate.

FutureChem Co.Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how FutureChem Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See FutureChem Co.Ltd (220100) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

FutureChem Co.Ltd Competitors by Total Liabilities

The table below lists competitors of FutureChem Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
Korea Information Certificate Authority Inc
KQ:053300
Korea ₩170.54 Billion
Softstar Entertainment
TWO:6111
Taiwan NT$21.04 Billion
Goltas Goller Bolgesi Cimento Sanayi ve Ticaret AS
IS:GOLTS
Turkey TL3.21 Billion
Peter Warren Automotive Holdings Ltd
AU:PWR
Australia AU$917.75 Million
Choppies Enterprises Ltd
JSE:CHP
South Africa ZAC2.70 Billion
SaraminHR Co.Ltd
KQ:143240
Korea ₩40.83 Billion
Payton Planar Magnetics Ltd
BR:PAY
Belgium €8.73 Million
Spruce Biosciences, Inc. Common Stock
NASDAQ:SPRB
USA $10.51 Million

Liability Composition Analysis (2016–2025)

This chart breaks down FutureChem Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FutureChem Co.Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.54 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how FutureChem Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for FutureChem Co.Ltd (2016–2025)

The table below shows the annual total liabilities of FutureChem Co.Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 ₩19.70 Billion
≈ $13.35 Million
-1.71%
2024-12-31 ₩20.04 Billion
≈ $13.58 Million
+124.71%
2023-12-31 ₩8.92 Billion
≈ $6.04 Million
-52.00%
2022-12-31 ₩18.58 Billion
≈ $12.59 Million
-23.91%
2021-12-31 ₩24.42 Billion
≈ $16.55 Million
-37.52%
2020-12-31 ₩39.08 Billion
≈ $26.49 Million
-24.91%
2019-12-31 ₩52.05 Billion
≈ $35.27 Million
+9.37%
2018-12-31 ₩47.59 Billion
≈ $32.25 Million
+440.85%
2017-12-31 ₩8.80 Billion
≈ $5.96 Million
+458.64%
2016-12-31 ₩1.58 Billion
≈ $1.07 Million
--

About FutureChem Co.Ltd

KQ:220100 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$115.79 Million
₩170.86 Billion KRW
Market Cap Rank
#18565 Global
#810 in Korea
Share Price
₩7620.00
Change (1 day)
+10.27%
52-Week Range
₩6910.00 - ₩34200.00
All Time High
₩34200.00
About

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more